ACANYA Drug Patent Profile

Which patents cover Acanya, and what generic alternatives are available?

Acanya is a drug marketed by Bausch and is included in one NDA. There are six patents protecting this drug.

This drug has twenty patent family members in fourteen countries.

The generic ingredient in ACANYA is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Acanya

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACANYA

International Patents:	20
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Drug Prices:	Drug price information for ACANYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACANYA
What excipients (inactive ingredients) are in ACANYA?	ACANYA excipients list
DailyMed Link:	ACANYA at DailyMed

See drug prices for ACANYA

See drug sales revenues for ACANYA

Recent Clinical Trials for ACANYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Taro Pharmaceuticals USA	Phase 1
Watson Laboratories, Inc.	Phase 3
Padagis LLC	Phase 3

See all ACANYA clinical trials

Pharmacology for ACANYA

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

US Patents and Regulatory Information for ACANYA

ACANYA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,288,434		Y
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	10,624,918
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,895,070

Expired US Patents for ACANYA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	5,733,886
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	6,117,843

International Patents for ACANYA

When does loss-of-exclusivity occur for ACANYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

European Patent Office

Japan

Mexico

Portugal

Russian Federation

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ACANYA around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201008265	TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT
Japan	5677693
Poland	171127

Supplementary Protection Certificates for ACANYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1586316	122011100019	Germany		PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID

ACANYA (clindamycin phosphate and tretinoin) Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What is ACANYA’s commercial profile in current market terms?

ACANYA is an FDA-approved fixed-dose combination topical gel (clindamycin phosphate 1.2% and tretinoin 0.025%) for acne vulgaris. The product’s commercial shape has been defined by (1) intense generic and brand competition in topical acne therapy, (2) reliance on dermatology and managed-care formularies, and (3) the practical barrier posed by topical combination complexity versus single-agent acne products.

ACANYA has not held the scale profile of the largest acne franchises in the U.S., and it trades more like a niche brand in a crowded topical category. That category mix matters: brand demand is typically most vulnerable when payer coverage shifts toward generics and when prescribers can achieve similar outcomes using lower-cost alternatives.

How do market dynamics pressure ACANYA’s demand and pricing power?

Managed care and formulary substitution

Topical acne products are frequently subject to tiering and step edits. ACANYA faces structural pressure from:

• Generic topical acne agents (single-ingredient retinoids, topical antibiotics, benzoyl peroxide combinations).
• Private-label and distributor-driven price competition in dermatology channels.
• Substitution toward lower-cost regimens that align with payer step therapy.

This dynamic usually limits ACANYA’s pricing leverage and increases the role of brand-specific differentiation (patient adherence, tolerability, and prescriber preference) in retaining volume.

Category competition and “attachment” economics

Topical acne therapy is a high-velocity category where prescribers frequently trial multiple options. Combination products can win when they reduce treatment friction (one tube vs multiple agents) and when outcomes justify the premium. But in practice, uptake is constrained when payers restrict coverage for combination brands.

For ACANYA, the practical outcome is:

• Brand growth is harder to sustain once generics saturate the first-line prescribing funnel.
• Sales depend more on formulary access (and pharmacy benefit manager rules) than on broad new prescriber adoption.

Who controls the supply-chain and commercialization risk?

ACANYA is marketed in the U.S. by Torii Pharmaceuticals America under an arrangement tied to its dermatology portfolio and commercialization footprint. That matters because smaller specialty brands typically carry higher exposure to channel and payer shifts than large multi-franchise portfolios.

What does the financial trajectory look like, and how has it changed over time?

Publicly observable sales pattern

The market-financial reality for niche dermatology brands like ACANYA is that sales trend tends to follow:

• Early adoption lift around launch and initial formulary wins,
• Plateau as generics expand,
• Gradual erosion if payer restrictions tighten, and
• Occasional inflection from contract wins or marketing/coverage adjustments.

ACANYA’s financial trajectory is consistent with a product that has remained a secondary franchise rather than a dominant category leader. This is visible in its ongoing presence as a “brand with pressure” rather than a high-growth SKU in mainstream dermatology ladders.

Share-of-voice vs category scale

Unlike major acne brands with stronger payer entrenchment or broader product line spillover, ACANYA is more exposed to:

• Dermatology prescriber churn,
• Payer step-edit tightening,
• Price competition when gross-to-net expands across promotional allowances.

That typically results in a muted topline outlook even when prescribing base holds.

How do patent and regulatory timelines affect ACANYA’s pricing and volume outlook?

ACANYA’s ability to sustain a brand premium depends on the residual legal and regulatory protections around its active combination and formulation. Once those protections narrow, the product’s economic model shifts from “premium pricing to defend share” toward “defend access to minimize volume loss.”

From a drug-patent perspective, topical combination products often face:

• Multiple patent families at different claim depths,
• Generics that can enter through carve-outs or design-around strategies,
• Delayed entry via settlement or stay mechanisms, followed by eventual erosion once stays expire.

What this means for financial trajectory

• If exclusivity windows compress further, incremental revenue becomes increasingly dependent on payer-specific contracts and patient out-of-pocket tolerability rather than on brand premium.
• If no new barriers emerge, sales typically flatten and drift downward in line with category generic penetration.

What market indicators matter most for ACANYA’s near-term revenue?

ACANYA’s near-term financial trajectory will be most sensitive to four measurable indicators:

1. Formulary tier placement across top commercial plans (whether ACANYA stays on preferred tiers).
2. Step therapy utilization (how often plans require trial of cheaper alternatives).
3. Channel inventory behavior (whether wholesalers discount to pharmacy).
4. Gross-to-net pressure (promo and rebate intensity shifting due to competitive entrants).

These indicators drive the gap between stable prescription writing and weaker net sales.

Where does ACANYA sit within the acne treatment competitive set?

ACANYA competes in the overlap zone between:

• Topical retinoids (adapalene, tretinoin products),
• Topical antibiotics (clindamycin-containing regimens),
• Combination acne therapies using benzoyl peroxide, retinoids, or multi-ingredient approaches.

The competitive center of gravity in acne is typically governed by:

• payer preference for lower-cost regimens,
• tolerability and irritation profiles,
• adherence outcomes that influence switching behavior.

ACANYA’s combination format can help in adherence, but its clinical differentiation must overcome the cost disadvantage under payer rules.

What is the actionable commercial outlook for investors and R&D planners?

Base case commercialization economics

For ACANYA, the most actionable expectation is:

• A revenue profile that tracks payer coverage and substitution dynamics more than innovation-driven adoption.
• Limited upside unless new payer access or differentiation programs materially shift net pricing.

Where new R&D investment tends to pay off in this space

In the topical acne category, the economic payoff for next-generation R&D typically comes from:

• Reduced irritation and improved adherence (lower discontinuation),
• Simplified dosing/regimens that fit payer step therapy,
• Evidence packages that support preferred formulary placement.

For established combination brands, value creation typically depends on extending market access rather than generating category-level demand expansion.

Key Takeaways

• ACANYA operates as a niche acne combination brand in a crowded topical category where generic substitution and formulary tiering usually limit pricing power.
• Its financial trajectory is governed primarily by managed-care coverage, step edits, and gross-to-net pressure rather than by broad category growth.
• Near-term revenue sensitivity concentrates in payer access metrics (preferred tier status, step therapy frequency) and channel/net pricing outcomes.
• The most likely economic path is plateau then gradual erosion unless payer coverage improves or product differentiation reduces switching.

FAQs

1. Is ACANYA positioned as a first-line topical acne therapy?
   It is used for acne vulgaris but competes in a payer-controlled environment where first-line positioning often shifts toward lower-cost generics and simpler regimens.

2. What drives ACANYA’s net sales more than list price?
   Gross-to-net effects, rebate/promo intensity, and formulary placement determine realized net revenue.

3. How does step therapy affect ACANYA demand?
   Step edits reduce direct uptake and increase trial of lower-cost alternatives, which typically erodes brand volume over time.

4. What competitive threats matter most for topical acne brands like ACANYA?
   Generic topical antibiotics/retinoids and payer-driven regimen substitution are the primary threats.

5. What patent or exclusivity factors most impact ACANYA’s financial outlook?
   Any narrowing or expiry of protection around the fixed-dose combination and its formulation increases generic entry risk and accelerates revenue erosion.

---

References

[1] U.S. Food and Drug Administration. ACANYA (clindamycin phosphate and tretinoin) topical gel, prescribing information.
[2] FDA Drug Approval Reports and labeling history for ACANYA (clindamycin phosphate and tretinoin).
[3] Torii Pharmaceuticals America. ACANYA product information and commercialization materials.